Base de dados : MEDLINE
Pesquisa : D04.210.500.745.432.719.260 [Categoria DeCS]
Referências encontradas : 68 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 7 ir para página                  

  1 / 68 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26267727
[Au] Autor:Keegan BR
[Ti] Título:Desoximetasone 0.25% Spray for the Relief of Scaling in Adults With Plaque Psoriasis.
[So] Source:J Drugs Dermatol;14(8):835-40, 2015 Aug.
[Is] ISSN:1545-9616
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Data from two Phase 3, double-blind, randomized, vehicle-controlled parallel studies were evaluated to determine the efficacy and safety of twice daily desoximetasone 0.25% spray for the treatment of plaque psoriasis. In addition to global disease assessments, scaling assessments were performed at baseline and at weeks 1, 2, and 4. To qualify for inclusion, subjects were required to have a clinical diagnosis of stable plaque psoriasis involving ≥10% of the body surface area (BSA), a combined target lesion severity score (TLSS) of ≥7 for the target lesion, a plaque elevation score of ≥3 (moderate) for the target lesion, and a Physician Global Assessment (PGA) score of 3 (moderate) or 4 (severe) at baseline for the overall disease severity. At the baseline visit, the mean proportions of BSA affected by psoriasis were 17% (range 10% to 86%) in the desoximetasone 0.25% spray group and 16% (range 10% to 70%) in the vehicle spray group. Approximately 90% of the patients in each group had moderate to very severe scaling at baseline. Desoximetasone 0.25% spray was effective with significant improvements in overall severity and was well tolerated, with dryness, irritation, and pruritus at the application site being the only reported adverse events occurring in >1% of patients, each of which occurred in less than 3% of patients. As a large proportion of psoriasis patients (94%) have reported being bothered by scaling, the relief of scaling was examined in these studies. At week 1, 69.7% of patients on desoximetasone 0.25% spray had scaling that was considered clear / almost clear / mild compared with 48.3% for those on vehicle spray ( P = .0027). By week 4, the proportion of patients with clear / almost clear / mild scaling had risen to 83.9% in the desoximetasone 0.25% spray group (P < .0001). After four weeks of treatment, 66.4% of patients in the topical corticosteroid group had an overall improvement of at least two grades of disease severity. This demonstrates that desoximetasone 0.25% spray provided fast and effective relief of scaling in patients with plaque psoriasis affecting 10% to 86% of their BSA.
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Desoximetasona/uso terapêutico
Psoríase/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Anti-Inflamatórios/administração & dosagem
Superfície Corporal
Desoximetasona/administração & dosagem
Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Meia-Idade
Psoríase/patologia
Índice de Gravidade de Doença
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 4E07GXB7AU (Desoximetasone)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:150813
[Lr] Data última revisão:
150813
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150813
[St] Status:MEDLINE


  2 / 68 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24691090
[Ti] Título:Serotonin antagonists for nausea and vomiting.
[So] Source:Gastroenterol Nurs;37(2):184-6, 2014 Mar-Apr.
[Is] ISSN:1538-9766
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Náusea/tratamento farmacológico
Antagonistas da Serotonina/uso terapêutico
Vômito/tratamento farmacológico
[Mh] Termos MeSH secundário: Desoximetasona/uso terapêutico
Granisetron/uso terapêutico
Seres Humanos
Indóis/uso terapêutico
Isoquinolinas/uso terapêutico
Ondansetron/uso terapêutico
Quinolizinas/uso terapêutico
Quinuclidinas/uso terapêutico
Antagonistas da Serotonina/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Indoles); 0 (Isoquinolines); 0 (Quinolizines); 0 (Quinuclidines); 0 (Serotonin Antagonists); 4AF302ESOS (Ondansetron); 4E07GXB7AU (Desoximetasone); 5D06587D6R (palonosetron); 82WI2L7Q6E (dolasetron); WZG3J2MCOL (Granisetron)
[Em] Mês de entrada:1505
[Cu] Atualização por classe:140402
[Lr] Data última revisão:
140402
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:140403
[St] Status:MEDLINE
[do] DOI:10.1097/SGA.0000000000000040


  3 / 68 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23852815
[Au] Autor:Kowalczyk P; Junco JJ; Kowalczyk MC; Sosnowska R; Tolstykh O; Walaszek Z; Hanausek M; Slaga TJ
[Ad] Endereço:Graduate School of Biomedical Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
[Ti] Título:The effects of dissociated glucocorticoids RU24858 and RU24782 on TPA-induced skin tumor promotion biomarkers in SENCAR mice.
[So] Source:Mol Carcinog;53(6):488-97, 2014 Jun.
[Is] ISSN:1098-2744
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Glucocorticoids (GCs) are very effective at preventing carcinogen- and tumor promoter-induced skin inflammation, hyperplasia, and mouse skin tumor formation. The effects of GCs are mediated by a well-known transcription factor, the glucocorticoid receptor (GR). GR acts via two different mechanisms: transcriptional regulation that requires DNA-binding (transactivation) and DNA binding-independent protein-protein interactions between GR and other transcription factors, such as nuclear factor kappa B (NF-κB) or activator protein 1 (AP-1; transrepression). We hypothesize that the transrepression activities of the GR are sufficient to suppress skin tumor promotion. We obtained two GCs (RU24858 and RU24782) that have dissociated downstream effects and induce only transrepression activities of the GR in a number of systems. These compounds bind the GR with high affinity and repress AP-1 and NF-κB activities while showing a lack of GR transactivation. RU24858, RU24782, or control full GCs desoximetasone (DES) and fluocinolone acetonide (FA) were applied to the dorsal skin of SENCAR mice prior to application of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA), two times per week for 2 weeks. DES, FA and RU24858 reversed TPA-induced epidermal hyperplasia and proliferation, while RU24782 treatment had no effect on these markers of skin tumor promotion. All tested compounds decreased TPA-induced c-jun mRNA levels in skin. DES, FA, and RU24858, but not RU24782, were also able to reverse TPA-induced increases in the mRNA levels of COX-2 and iNOS. These findings show that RU24858 but not RU24782 reduced TPA-induced epidermal hyperplasia, proliferation, and inflammation, while both compounds reversed c-jun mRNA increases in the skin.
[Mh] Termos MeSH primário: Transformação Celular Neoplásica/efeitos dos fármacos
Transformação Celular Neoplásica/metabolismo
Desoximetasona/análogos & derivados
Glucocorticoides/farmacologia
Neoplasias Cutâneas/metabolismo
[Mh] Termos MeSH secundário: Animais
Animais não Endogâmicos
Anticarcinógenos/química
Anticarcinógenos/farmacologia
Biomarcadores
Proliferação Celular/efeitos dos fármacos
Ciclo-Oxigenase 2/genética
Desoximetasona/química
Desoximetasona/farmacologia
Epiderme/efeitos dos fármacos
Epiderme/patologia
Feminino
Regulação da Expressão Gênica/efeitos dos fármacos
Glucocorticoides/química
Hiperplasia
Interleucina-6/genética
Camundongos
Óxido Nítrico Sintase Tipo II/genética
Proteínas Proto-Oncogênicas c-jun/genética
RNA Mensageiro
Neoplasias Cutâneas/induzido quimicamente
Neoplasias Cutâneas/genética
Acetato de Tetradecanoilforbol/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Anticarcinogenic Agents); 0 (Biomarkers); 0 (Glucocorticoids); 0 (Interleukin-6); 0 (Proto-Oncogene Proteins c-jun); 0 (RNA, Messenger); 0 (RU24782); 0 (RU24858); 4E07GXB7AU (Desoximetasone); EC 1.14.13.39 (Nitric Oxide Synthase Type II); EC 1.14.99.1 (Cyclooxygenase 2); NI40JAQ945 (Tetradecanoylphorbol Acetate)
[Em] Mês de entrada:1406
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130716
[St] Status:MEDLINE
[do] DOI:10.1002/mc.22002


  4 / 68 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:24301242
[Au] Autor:Kircik L; Lebwohl MG; Del Rosso JQ; Bagel J; Stein Gold L; Weiss JS
[Ti] Título:Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasis.
[So] Source:J Drugs Dermatol;12(12):1404-10, 2013 Dec.
[Is] ISSN:1545-9616
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Two Phase 3, double-blind, randomized, vehicle-controlled parallel studies evaluated the efficacy and safety of desoximetasone spray 0.25%, a super-potent topical corticosteroid, twice daily vs vehicle spray twice daily for 28 days in adult patients with moderate to severe plaque psoriasis. At baseline and throughout the study, the severity of disease for the psoriatic lesions was assessed using the Physician Global Assessment (PGA) score and a target lesion was assessed using the Total Lesion Severity Score (TLSS). A designated psoriatic plaque lesion was selected as the target lesion upon enrollment and evaluated throughout the study to determine the TLSS. To qualify for study entry, the subject needed to exhibit a PGA score of 3 (moderate) or 4 (severe) for overall disease severity, and a target lesion with an area of at least 5 cm(2) that achieved a combined score TLSS of >=7, with a plaque elevation score of >=3 (at least moderate). The mean % BSA affected by psoriasis ranged from 13%-17% at baseline. In both Phase 3 studies, a statistically significantly greater percentage of subjects in the desoximetasone spray 0.25% compared to vehicle group achieved both Clinical Success and Treatment Success at Day 28. These results, which were the primary efficacy variables, demonstrated superior efficacy in the active study group for both overall improvement of plaque psoriasis (by PGA) and in the individual psoriasis lesion (by TLSS) designated at baseline as the most severely involved plaque (target lesion). Assessment of secondary efficacy variables in both Phase 3 studies showed that subjects receiving desoximetasone Spray 0.25% twice daily exhibited statistically significantly mean changes from Baseline to Day 28 in PGA, TLSS, and % BSA affected when compared to subjects receiving vehicle spray twice daily. Tolerability and safety were assessed at all study visits. No statistically significant differences were observed between study arms and no major safety signals related to AEs were noted. No stinging and burning were reported with the spray formulation. This Class I topical corticosteroid has shown to be safe and efficacious in moderate to severe plaque psoriasis.
[Mh] Termos MeSH primário: Fármacos Dermatológicos/uso terapêutico
Desoximetasona/uso terapêutico
Glucocorticoides/uso terapêutico
Psoríase/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Cutânea
Adulto
Idoso
Idoso de 80 Anos ou mais
Fármacos Dermatológicos/administração & dosagem
Fármacos Dermatológicos/efeitos adversos
Desoximetasona/administração & dosagem
Desoximetasona/efeitos adversos
Método Duplo-Cego
Feminino
Glucocorticoides/administração & dosagem
Glucocorticoides/efeitos adversos
Seres Humanos
Masculino
Psoríase/patologia
Índice de Gravidade de Doença
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Glucocorticoids); 4E07GXB7AU (Desoximetasone)
[Em] Mês de entrada:1408
[Cu] Atualização por classe:131204
[Lr] Data última revisão:
131204
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131205
[St] Status:MEDLINE


  5 / 68 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:22747717
[Au] Autor:Serbezov V
[Ad] Endereço:VSS-VS Ltd., Plovdiv, Bulgaria, Veliko Turnovo Str. 55 A. serbezov@plov.net
[Ti] Título:Pulsed laser deposition: the road to hybrid nanocomposites coatings and novel pulsed laser adaptive technique.
[So] Source:Recent Pat Nanotechnol;7(1):26-40, 2013 Jan.
[Is] ISSN:2212-4020
[Cp] País de publicação:United Arab Emirates
[La] Idioma:eng
[Ab] Resumo:The applications of Pulsed Laser Deposition (PLD) for producing nanoparticles, nanostructures and nanocomposites coatings based on recently developed laser ablating techniques and their convergence are being reviewed. The problems of in situ synthesis of hybrid inorganic-organic nanocomposites coatings by these techniques are being discussed. The novel modification of PLD called Pulsed Laser Adaptive Deposition (PLAD) technique is presented. The in situ synthesized inorganic/organic nanocomposites coatings from Magnesium (Mg) alloy/Rhodamine B and Mg alloy/ Desoximetasone by PLAD are described. The trends, applications and future development of discussed patented methods based on the laser ablating technologies for producing hybrid nanocomposite coatings have also been discussed in this review.
[Mh] Termos MeSH primário: Lasers
Nanocompostos/química
[Mh] Termos MeSH secundário: Ligas/química
Desoximetasona/química
Magnésio/química
Metais/química
Patentes como Assunto
Rodaminas/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Alloys); 0 (Metals); 0 (Rhodamines); 4E07GXB7AU (Desoximetasone); I38ZP9992A (Magnesium)
[Em] Mês de entrada:1306
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120704
[St] Status:MEDLINE


  6 / 68 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23214328
[Au] Autor:Stojkovic T; Binic I; Tiodorovic J
[Ad] Endereço:Visoka medicinska skola strukovnih studija, Cuprija, Klinicki centar, Nis. tannya@sbb.rs
[Ti] Título:[Evaluation of effect of local administration of desoximetasone and ditranol in psoriatic lesion byapplying 20 MHz ultrasound].
[So] Source:Med Pregl;65(9-10):368-72, 2012 Sep-Oct.
[Is] ISSN:0025-8105
[Cp] País de publicação:Serbia
[La] Idioma:srp
[Ab] Resumo:INTRODUCTION: This prospective study was aimed at examining the modification of ultrasound characteristics of psoriatic plaques during desoximetasone and dithranol treatment. MATERIAL AND METHODS: The examination included 50 patients with chronic plaque-type psoriasis to whom 0.25% desoximetasone and dithranol was applied on the psoriatic lesions in the period of 21 days. The changes were measured before and every 7 days after the beginning of therapy by the combined application of A- and B-mode echosonography. RESULTS. At the beginning of the examination, the average values of the enter echo were 0.67 +/- 0.53 mm; hypoehogen shadow 0.30 +/- 0.11 mm, and dermis thickness 3.03 +/- 1.05 mm. On the first check up, the average values of the enter echo were 0.45 +/- 0.29 mm; hypoechogen shadow 0.23 +/- 0.08 mm and dermis thickness 2.65 +/- 0.97 mm. On the second check up, the average values of the enter echo were 0.30 +/- 0.18 mm; hypoechogen shadow 0.21 +/- 0.18 mm, dermis thickness 2.18 +/- 0.82 mm. On the third check up, the average values of the enter echo were 0.24 +/- 0.17 mm; hypoechogen shadow 0.18 +/- 0.17 mm, and dermis thickness 1.8 +/- 0.69 mm. DISCUSSION. The evaluation of the ultrasonographic characteristics revealed a significant reduction in the values in the course of the examination. Statistically significant differences were found before, during, and at the end of the examination by recording the ultrasound parameters of the epidermis and dermis and by following their modification. CONCLUSION. Precise determination of ultrasound parameters of epidermis and dermis and the possibility of recording their modification in a shorter or longer time interval can be used for monitoring and assessment of therapy effect of a medication.
[Mh] Termos MeSH primário: Antralina/administração & dosagem
Anti-Inflamatórios/administração & dosagem
Fármacos Dermatológicos/administração & dosagem
Desoximetasona/administração & dosagem
Glucocorticoides/administração & dosagem
Psoríase/tratamento farmacológico
Pele/diagnóstico por imagem
[Mh] Termos MeSH secundário: Administração Cutânea
Feminino
Seres Humanos
Masculino
Meia-Idade
Psoríase/diagnóstico por imagem
Ultrassonografia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Dermatologic Agents); 0 (Glucocorticoids); 4E07GXB7AU (Desoximetasone); U8CJK0JH5M (Anthralin)
[Em] Mês de entrada:1301
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:121211
[St] Status:MEDLINE


  7 / 68 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:22214335
[Au] Autor:Reeves EK; Rayavarapu S; Damsker JM; Nagaraju K
[Ad] Endereço:ReveraGen BioPharma, Inc., Rockville, MD, USA.
[Ti] Título:Glucocorticoid analogues: potential therapeutic alternatives for treating inflammatory muscle diseases.
[So] Source:Endocr Metab Immune Disord Drug Targets;12(1):95-103, 2012 Mar.
[Is] ISSN:2212-3873
[Cp] País de publicação:United Arab Emirates
[La] Idioma:eng
[Ab] Resumo:Glucocorticoids (GCs) have been prescribed to treat a variety of diseases, including inflammatory myopathies and Duchenne muscular dystrophy for over 50 years. However, their prescription remains controversial due to the significant side effects associated with the chronic treatment. It is a common belief that the clinical efficacy of GCs is due to their transrepression of pro-inflammatory genes through inhibition of inflammatory transcription factors (i.e. NF-κB, AP-1) whereas the adverse side effects are attributed to the glucocorticoid receptor (GR)-mediated transcription of target genes (transactivation). The past decade has seen an increased interest in the development of GR modulators that maintain the effective anti-inflammatory properties but lack the GR-dependent transcriptional response as a safe alternative to traditional GCs. Many of these analogues or "dissociative" compounds show potential promise in in vitro studies but fail to reach human clinical trials. In this review, we discuss molecular effects of currently prescribed GCs on skeletal muscle and also discuss the current state of development of GC analogues as alternative therapeutics for inflammatory muscle diseases.
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Glucocorticoides
Miosite/tratamento farmacológico
[Mh] Termos MeSH secundário: Benzofuranos/farmacologia
Benzopiranos/farmacologia
Benzopiranos/uso terapêutico
Benzoxazinas/farmacologia
Compostos de Benzilideno/farmacologia
Compostos de Benzilideno/uso terapêutico
Desoximetasona/análogos & derivados
Glucocorticoides/efeitos adversos
Glucocorticoides/agonistas
Glucocorticoides/química
Glucocorticoides/uso terapêutico
Seres Humanos
Hidroxicorticosteroides/farmacologia
Hidroxicorticosteroides/uso terapêutico
Terapia de Alvo Molecular/tendências
Quinolinas/farmacologia
Quinolinas/uso terapêutico
Receptores de Glucocorticoides/agonistas
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.; REVIEW
[Nm] Nome de substância:
0 (10-methoxy-5-(2-propenyl)-2,5-dihydro-2,2,4-trimethyl-1H-(1)benzopyrano(3,4-f)quinoline); 0 (5-((2-fluoro-3-methylphenyl)methylene)-2,5-dihydro-10-methoxy-2,2,4-trimethyl-1H-(1)benzopyrano(3,4-f)quinolin-9-ol); 0 (Anti-Inflammatory Agents); 0 (Benzofurans); 0 (Benzopyrans); 0 (Benzoxazines); 0 (Benzylidene Compounds); 0 (Glucocorticoids); 0 (Hydroxycorticosteroids); 0 (Quinolines); 0 (RU24858); 0 (Receptors, Glucocorticoid); 0 (ZK 216348); 4E07GXB7AU (Desoximetasone)
[Em] Mês de entrada:1207
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120105
[St] Status:MEDLINE


  8 / 68 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21848604
[Au] Autor:Cheng YP; Sun CC; Liao YH
[Ti] Título:Diagnosis and treatment of radiation port dermatophytosis of scalp: a case report.
[So] Source:Mycoses;55(2):e27-8, 2012 Mar.
[Is] ISSN:1439-0507
[Cp] País de publicação:Germany
[La] Idioma:eng
[Mh] Termos MeSH primário: Radiodermatite/diagnóstico
Couro Cabeludo/microbiologia
Tinha do Couro Cabeludo/diagnóstico
Trichophyton
[Mh] Termos MeSH secundário: Antifúngicos/administração & dosagem
Antifúngicos/uso terapêutico
Astrocitoma/radioterapia
Astrocitoma/cirurgia
Neoplasias Encefálicas/radioterapia
Neoplasias Encefálicas/cirurgia
Desoximetasona/administração & dosagem
Diagnóstico Diferencial
Glucocorticoides/administração & dosagem
Seres Humanos
Itraconazol/administração & dosagem
Itraconazol/uso terapêutico
Masculino
Meia-Idade
Radiodermatite/tratamento farmacológico
Radiodermatite/microbiologia
Tinha do Couro Cabeludo/tratamento farmacológico
Tinha do Couro Cabeludo/microbiologia
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Glucocorticoids); 304NUG5GF4 (Itraconazole); 4E07GXB7AU (Desoximetasone)
[Em] Mês de entrada:1305
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110819
[St] Status:MEDLINE
[do] DOI:10.1111/j.1439-0507.2011.02087.x


  9 / 68 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:18591846
[Au] Autor:Kitahara A; Saga K; Koide S; Isobe T; Oki Y; Nakamura H
[Ad] Endereço:Department of Endocrinology, Kitahara Medical Clinic, Hamamatsu, Japan. kitahara-endo@umin.ac.jp
[Ti] Título:Iatrogenic hyperadrenocorticism and steatohepatitis caused by unapproved medicine.
[So] Source:Intern Med;47(13):1231-6, 2008.
[Is] ISSN:1349-7235
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:A 54-year-old man experienced weight gain. He was diagnosed as having hyperglycemia, hypertension and liver damage. Liver biopsy showed steatohepatitis. We initially suspected him as having hyperadrenocorticism. However, both adrenocorticotropic hormone and cortisol levels were low. Later, it was revealed that he took medicine to relieve his gonalgia. His hyperglycemia, hypertension and liver damage improved after he discontinued taking the medicine. An analysis of this medicine showed that it contained desoximetasone, a glucocorticoid compound that had not been approved for medical use in Japan. To adequately diagnose clinical conditions, it is necessary to survey the patient's medicinal history in detail.
[Mh] Termos MeSH primário: Hiperfunção Adrenocortical/induzido quimicamente
Doença Hepática Induzida por Substâncias e Drogas/etiologia
Desoximetasona/efeitos adversos
Fígado Gorduroso/induzido quimicamente
Glucocorticoides/efeitos adversos
Automedicação/efeitos adversos
[Mh] Termos MeSH secundário: Artralgia/tratamento farmacológico
Seres Humanos
Articulação do Joelho
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 4E07GXB7AU (Desoximetasone)
[Em] Mês de entrada:0808
[Cu] Atualização por classe:161124
[Lr] Data última revisão:
161124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080702
[St] Status:MEDLINE


  10 / 68 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:18523415
[Au] Autor:Borelli C; Gassmueller J; Fluhr JW; Nietsch KH; Schinzel S; Korting HC
[Ad] Endereço:Klinik und Poliklinik für Dermatologie und Allergologie der Ludwig-Maximilians-Universität, München, Deutschland. claudia.borelli@med.uni-muenchen.de
[Ti] Título:Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay.
[So] Source:Skin Pharmacol Physiol;21(3):181-7, 2008.
[Is] ISSN:1660-5535
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: We report on a double-blind, vehicle-controlled, single-center confirmatory study with random assignment. The purpose of the study was to investigate the topical bioavailability of different topical corticosteroid formulations in healthy human beings focussing on desoximetasone (DM). MATERIALS AND METHODS: Two DM 0.25% formulations [ointment (DM-o) and fatty ointment (DM-fo, water-free); class III corticosteroids], the corresponding active ingredient-free vehicles and three comparators of different strength [clobetasol propionate 0.05% (CP 0.05%), fatty ointment, class IV; hydrocortisone (HC) 1%, fatty ointment, class I, and betamethasone (BM) 0.05%, fatty ointment, class III] were tested using the vasoconstriction assay. The degree of vasoconstriction (blanching) in the treatment field was compared to the one found in untreated control fields using chromametric measurements and clinical assessment. RESULTS/CONCLUSION: DM-o 0.25%, DM-fo 0.25% and BM 0.05% showed similar vasoconstrictive potential, i.e., clear blanching. In fact, both DM preparations were proven to be noninferior to BM 0.05%, while CP 0.05% was found a little less active. HC 1.0% and the DM vehicles showed no clear-cut vasoconstrictive effect. No adverse events related to the study medications were observed. Good topical bioavailability of both DM formulations was detected by chromametric measurement and clinical assessment.
[Mh] Termos MeSH primário: Anti-Inflamatórios/farmacologia
Betametasona/farmacologia
Clobetasol/farmacologia
Desoximetasona/farmacologia
Hidrocortisona/farmacologia
Pele/irrigação sanguínea
Vasoconstrição/efeitos dos fármacos
Vasoconstritores/farmacologia
[Mh] Termos MeSH secundário: Administração Cutânea
Adolescente
Adulto
Idoso
Anti-Inflamatórios/administração & dosagem
Anti-Inflamatórios/metabolismo
Betametasona/administração & dosagem
Betametasona/metabolismo
Disponibilidade Biológica
Clobetasol/administração & dosagem
Clobetasol/metabolismo
Desoximetasona/administração & dosagem
Desoximetasona/metabolismo
Método Duplo-Cego
Feminino
Seres Humanos
Hidrocortisona/administração & dosagem
Hidrocortisona/metabolismo
Masculino
Meia-Idade
Veículos Farmacêuticos
Absorção Cutânea
Vasoconstritores/administração & dosagem
Vasoconstritores/metabolismo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Pharmaceutical Vehicles); 0 (Vasoconstrictor Agents); 4E07GXB7AU (Desoximetasone); 9842X06Q6M (Betamethasone); ADN79D536H (Clobetasol); WI4X0X7BPJ (Hydrocortisone)
[Em] Mês de entrada:0808
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080605
[St] Status:MEDLINE
[do] DOI:10.1159/000131082



página 1 de 7 ir para página                  
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde